NYSE:PLX Protalix BioTherapeutics (PLX) Stock Price, News & Analysis $1.14 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.14▼$1.1650-Day Range$1.04▼$1.2952-Week Range$1.02▼$2.09Volume104,093 shsAverage Volume413,578 shsMarket Capitalization$83.95 millionP/E Ratio28.63Dividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Protalix BioTherapeutics alerts: Email Address Protalix BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside773.4% Upside$10.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth425.00%From $0.12 to $0.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 starsMedical Sector513th out of 936 stocksBiological Products, Except Diagnostic Industry78th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingProtalix BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageProtalix BioTherapeutics has received no research coverage in the past 90 days.Read more about Protalix BioTherapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PLX. Previous Next 0.0 Dividend Strength Dividend YieldProtalix BioTherapeutics does not currently pay a dividend.Dividend GrowthProtalix BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PLX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 5 people have searched for PLX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows1 people have added Protalix BioTherapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Protalix BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.97% of the stock of Protalix BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.53% of the stock of Protalix BioTherapeutics is held by institutions.Read more about Protalix BioTherapeutics' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Protalix BioTherapeutics are expected to grow by 425.00% in the coming year, from $0.12 to $0.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Protalix BioTherapeutics is 28.63, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.95.Price to Earnings Ratio vs. SectorThe P/E ratio of Protalix BioTherapeutics is 28.63, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 150.64.Price to Book Value per Share RatioProtalix BioTherapeutics has a P/B Ratio of 2.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Protalix BioTherapeutics Stock (NYSE:PLX)Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Read More PLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLX Stock News HeadlinesJune 13, 2024 | prnewswire.comProtalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled GoutMay 29, 2024 | prnewswire.comProtalix BioTherapeutics to Present at the 2024 BIO International ConventionJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 15, 2024 | finance.yahoo.comPLX: First Quarter UpdateMay 13, 2024 | finance.yahoo.comProtalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 12, 2024 | investing.comEarnings call: Protalix BioTherapeutics Q1 2024 financial resultsMay 11, 2024 | finance.yahoo.comProtalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | investorplace.comPLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 10, 2024 | msn.comNovavax, Macrogenics, Biofrontera among healthcare moversMay 10, 2024 | msn.comStocks See Support from Higher Chip Stocks and Earnings OptimismMay 10, 2024 | markets.businessinsider.comProtalix BioTherapeutics Inc. Q1 Loss Increases, Misses EstimatesMay 10, 2024 | prnewswire.comProtalix BioTherapeutics Reports First Quarter 2024 Financial and Business ResultsMay 9, 2024 | markets.businessinsider.comProtalix BioTherapeutics earnings: here's what Wall Street expectsMay 3, 2024 | finance.yahoo.comProtalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024March 16, 2024 | seekingalpha.comProtalix BioTherapeutics, Inc. (PLX) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | uk.investing.comEarnings call: Protalix BioTherapeutics reports fiscal year 2023 resultsMarch 15, 2024 | ca.finance.yahoo.comProduction cuts, geopolitical tensions drive oil rallySee More Headlines Receive PLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalix BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PLX CUSIPN/A CIK1006281 Webwww.protalix.com Phone201-696-9345Fax972-4988-9489Employees208Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+762.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio29.00 Forward P/E Ratio9.67 P/E GrowthN/ANet Income$8.31 million Net Margins11.48% Pretax Margin11.35% Return on Equity19.48% Return on Assets7.82% Debt Debt-to-Equity RatioN/A Current Ratio1.38 Quick Ratio0.97 Sales & Book Value Annual Sales$65.49 million Price / Sales1.30 Cash Flow$0.14 per share Price / Cash Flow8.50 Book Value$0.47 per share Price / Book2.47Miscellaneous Outstanding Shares73,320,000Free Float69,672,000Market Cap$85.05 million OptionableOptionable Beta0.78 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Dror Bashan (Age 57)President, CEO & Director Comp: $1.38MMr. Eyal Rubin M.B.A. (Age 48)Senior VP, CFO, Treasurer & Corporate Secretary Comp: $686.78kMr. Yaron Naos (Age 60)Senior Vice President of Operations Comp: $513.82kMs. Yael FellousVice President of Human ResourcesKey CompetitorsPoseida TherapeuticsNASDAQ:PSTXSutro BiopharmaNASDAQ:STROJasper TherapeuticsNASDAQ:JSPRScilexNASDAQ:SCLXAdaptimmune TherapeuticsNASDAQ:ADAPView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 157,516 shares on 5/20/2024Ownership: 0.215%SG Americas Securities LLCSold 13,139 shares on 5/7/2024Ownership: 0.029%GSA Capital Partners LLPSold 50,667 shares on 5/3/2024Ownership: 0.673%Dror BashanBought 64,516 shares on 10/19/2023Total: $90,322.40 ($1.40/share)View All Insider TransactionsView All Institutional Transactions PLX Stock Analysis - Frequently Asked Questions How have PLX shares performed this year? Protalix BioTherapeutics' stock was trading at $1.78 on January 1st, 2024. Since then, PLX shares have decreased by 35.7% and is now trading at $1.1450. View the best growth stocks for 2024 here. How were Protalix BioTherapeutics' earnings last quarter? Protalix BioTherapeutics, Inc. (NYSE:PLX) released its quarterly earnings data on Friday, May, 10th. The company reported ($0.06) earnings per share for the quarter. The firm had revenue of $3.75 million for the quarter. Protalix BioTherapeutics had a trailing twelve-month return on equity of 19.48% and a net margin of 11.48%. When did Protalix BioTherapeutics' stock split? Protalix BioTherapeutics shares reverse split on Friday, December 20th 2019. The 1-10 reverse split was announced on Monday, December 9th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Protalix BioTherapeutics? Shares of PLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PLX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.